DXCM logo DexCom +
DexCom
+

DexCom (DXCM) Business News

Track DexCom in real time with a live news feed covering DexCom stock news, official press releases, company announcements, and an archive of historical DexCom news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

Business Wire

4:30 PM | Monday | Sep 14, 2026

news photo
Loading...

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.

Read full article redirect
4:30 PM | Monday | Sep 14, 2026

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.

Read full article arrow
News Thumbnail
4:30 PM | Monday | Sep 14, 2026

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.

Read full article arrow
News Thumbnail
4:15 PM | Thursday | Sep 10, 2026

Dexcom Appoints Glenn Boehnlein to Board of Directors

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world's leading medical technology.

Read full article arrow
News Thumbnail
3:27 PM | Monday | Sep 7, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Read full article arrow
News Thumbnail
8:30 AM | Tuesday | Sep 1, 2026

Dexcom Announces Upcoming Conference Presentation

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live presentation is scheduled to begin at approximately 8:00 AM EDT and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.
com and will be archived there for future reference. About DexCom, Inc. Dexcom em.

Read full article arrow
News Thumbnail
4:02 PM | Thursday | Jul 30, 2026

Dexcom Reports Second Quarter 2026 Financial Results

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.

Read full article arrow
News Thumbnail
9:12 AM | Wednesday | Jul 29, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 23, 2026

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.

Read full article arrow
News Thumbnail
5:15 PM | Wednesday | Jul 22, 2026

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom.

Read full article arrow
News Thumbnail
4:45 PM | Monday | Jul 13, 2026

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Business Wire

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Jul 9, 2026

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day.
The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Read full article arrow
News Thumbnail